Loading clinical trials...
Loading clinical trials...
A Two-Way Crossover, Open-Label, Single-Dose Fasting, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-smoking Male and Female Subjects.
Conditions
Interventions
Cefadroxil 500 mg Capsules
DURICEF® capsules 500 mg
Locations
2
United States
Bioassay Laboratory, Inc.
Houston, Texas, United States
Biovail Contract Research
Toronto, Ontario, Canada
Start Date
September 1, 2004
Primary Completion Date
October 1, 2004
Completion Date
October 1, 2004
Last Updated
August 19, 2024
NCT00090662
NCT06290258
NCT06716502
NCT07310264
NCT07483606
NCT06342713
Lead Sponsor
Teva Pharmaceuticals USA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions